Ceretin: creating the next generation
Cognitive enhancement is all about improvement. The next step. The next development. The next leap forward. At Cognivia, we're preparing to make that leap with our latest iterations of Ceretin.
Ceretin is one of the world's most popular drugs, dominating the cognitive enhancement market. It has changed the lives of millions and is, without a doubt, one of the most significant developments in medical history.
But the Ceretin tablets you use today are very different from those that first hit the shelves nine years ago - very different and much improved. This is already the fourth generation of Ceretin, and there is still room for further advances.
The next advance is well on the way. Ceretin 5 is going through Phase 3 testing and is likely to be certified and released next year. Our thorough programme of testing has established that Ceretin 5 will offer an amazing 10% improvement across all aspects of cognitive performance, compared with the current generation.
We're now looking at ways of adopting these breakthroughs to further enhance the efficacy of Mnemosyne, Cardinal and Expedin.
And even more exciting developments lie ahead. Ceretin 6 is currently undergoing Phase 1 testing, and some of the results have been astonishing. Performance has been enhanced by as much as 70% over Ceretin 4, with longer-lasting effects. Indeed, one of the aims of the testing stage is to identify a dosage that will be commensurate with Ceretin 4's 24-hour period of enhancement.
At this experimental stage, we're working with new copper and selenium compounds to produce greater alertness, counterbalanced by slow-release vitamin compounds. Preliminary results suggest that the modified formula will also boost short-term memory with no side effects.
The non-dopaminergic effects have been strengthened, not only leading to sharper performance, but also offering a potential remedy for long-term neurotransmission problems associated with degenerative disease. The implications of this are yet to be fully established, but the possibilities are extremely exciting.
Ceretin 5 was submitted to the PCAG for inclusion in this year's competitor testing programme, and the PCAG have again been instrumental in our development process for Ceretin 6.
Naturally, testing a new generation of drug is a complex process - especially when we have made so many simultaneous improvements to the formula. Our aim is to identify and eliminate any possible issues in Phase 1 before moving onto the next stage. That's why we believe that issues found at this stage are good news, not cause for concern. Our priority is always safety, even if it means that the production schedule must sometimes take second place.
Each successive generation of Ceretin has enjoyed a longer and longer shelf life. Ceretin 4 continues to be extremely popular, more than two years after its release. The imminent arrival of Ceretin 5 will give both customers and shareholders a safe and substantial boost, and could satisfy the public for years to come - giving us plenty of time to develop the sixth generation.
Drug testing has one overarching purpose: to protect the public. Cognivia takes that responsibility seriously, and we would never rush a product onto the shelves without thoroughly assessing and eradicating any risks. We've spent years earning the trust of our customers. We wouldn't risk losing that.
about our features
At Cognivia, we know how important it is for the public to understand and discuss all of the issues involved in cognitive enhancement. Our scientists play a pivotal role in engaging in dialogue with the public about the research we conduct and the products we develop. The feature articles section we publish here is just one of the ways in which we ensure Perplex City is fully informed of the huge impact that cognitive enhancement can have on our lives.